*Glaxosmithkline Pharmaceuticals Ltd.* | *CMP* Rs. 1516 | *M Cap* Rs. 25677 Cr | *52 W H/L* 1808/1190
(Nirmal Bang Retail Research)
*Result is in-line with expectations*
Revenue from Operations came at Rs. 813.8 Cr (-5.1% QoQ, 4.9% YoY) vs expectation of Rs. 818.1 Cr, QoQ Rs. 857.2 Cr, YoY Rs. 775.8 Cr
EBIDTA came at Rs. 170.9 Cr (-16.8% QoQ, -1.5% YoY) vs expectation of Rs. 172.9 Cr, QoQ Rs. 205.5 Cr, YoY Rs. 173.6 Cr
EBITDA Margin came at 21% vs expectation of 21.1%, QoQ 24%, YoY 22.4%
Adj. PAT came at Rs. 133.3 Cr vs expectation of Rs. 126.4 Cr, QoQ Rs. 146 Cr, YoY Rs. 126.8 Cr
Quarter EPS is Rs. 7.9
Share is trading at P/E of 39.7x FY22E EPS
(Nirmal Bang Retail Research)
*Result is in-line with expectations*
Revenue from Operations came at Rs. 813.8 Cr (-5.1% QoQ, 4.9% YoY) vs expectation of Rs. 818.1 Cr, QoQ Rs. 857.2 Cr, YoY Rs. 775.8 Cr
EBIDTA came at Rs. 170.9 Cr (-16.8% QoQ, -1.5% YoY) vs expectation of Rs. 172.9 Cr, QoQ Rs. 205.5 Cr, YoY Rs. 173.6 Cr
EBITDA Margin came at 21% vs expectation of 21.1%, QoQ 24%, YoY 22.4%
Adj. PAT came at Rs. 133.3 Cr vs expectation of Rs. 126.4 Cr, QoQ Rs. 146 Cr, YoY Rs. 126.8 Cr
Quarter EPS is Rs. 7.9
Share is trading at P/E of 39.7x FY22E EPS
*Aarti Industries Ltd.* | *CMP* Rs. 1746 | *M Cap* Rs. 30421 Cr | *52 W H/L* 1815/850
(Nirmal Bang Retail Research)
*Result is marginally below expectations*
*Gross Margin remain Stable QoQ, higher other expenses led to decline in EBITDA margin*
Revenue from Operations came at Rs. 1209.4 Cr (1.9% QoQ, 12.4% YoY) vs expectation of Rs. 1247.8 Cr, QoQ Rs. 1186.8 Cr, YoY Rs. 1076.2 Cr
EBIDTA came at Rs. 260.3 Cr (-8.7% QoQ, 18.9% YoY) vs expectation of Rs. 296.5 Cr, QoQ Rs. 285 Cr, YoY Rs. 218.9 Cr
EBITDA Margin came at 21.5% vs expectation of 23.8%, QoQ 24%, YoY 20.3%
Adj. PAT came at Rs. 139.3 Cr vs expectation of Rs. 178.7 Cr, QoQ Rs. 165.3 Cr, YoY Rs. 110.4 Cr
Quarter EPS is Rs. 8
Share is trading at P/E of 43.4x FY22E EPS
(Nirmal Bang Retail Research)
*Result is marginally below expectations*
*Gross Margin remain Stable QoQ, higher other expenses led to decline in EBITDA margin*
Revenue from Operations came at Rs. 1209.4 Cr (1.9% QoQ, 12.4% YoY) vs expectation of Rs. 1247.8 Cr, QoQ Rs. 1186.8 Cr, YoY Rs. 1076.2 Cr
EBIDTA came at Rs. 260.3 Cr (-8.7% QoQ, 18.9% YoY) vs expectation of Rs. 296.5 Cr, QoQ Rs. 285 Cr, YoY Rs. 218.9 Cr
EBITDA Margin came at 21.5% vs expectation of 23.8%, QoQ 24%, YoY 20.3%
Adj. PAT came at Rs. 139.3 Cr vs expectation of Rs. 178.7 Cr, QoQ Rs. 165.3 Cr, YoY Rs. 110.4 Cr
Quarter EPS is Rs. 8
Share is trading at P/E of 43.4x FY22E EPS
Route Mobile Concall Update
*Outlook – Positive*
Management guides for a revenue growth of 20% organically in FY22. Volume growth would be 10-15%. Focus would be majority towards improving gross margin . Q4FY21 gross margin improved to 22% vs 18% QoQ owing passing on DLT charges to customers which had taken a hit last quarter. Gross margin of 22% is sustainable . With change in product mix management aspires to reach gross margin of 25%.
Share is trading at P/E of 54x FY22E EPS
*Outlook – Positive*
Management guides for a revenue growth of 20% organically in FY22. Volume growth would be 10-15%. Focus would be majority towards improving gross margin . Q4FY21 gross margin improved to 22% vs 18% QoQ owing passing on DLT charges to customers which had taken a hit last quarter. Gross margin of 22% is sustainable . With change in product mix management aspires to reach gross margin of 25%.
Share is trading at P/E of 54x FY22E EPS
*Minda Corporation Ltd.* | *CMP* Rs. 111 | *M Cap* Rs. 2642 Cr | *52 W H/L* 114/54
(Nirmal Bang Retail Research)
*Result is above expectations*
Revenue from Operations came at Rs. 794.1 Cr (7.3% QoQ, 13.8% YoY) vs expectation of Rs. 740.7 Cr, QoQ Rs. 739.8 Cr, YoY Rs. 697.9 Cr
Gross Profit Margins came at 36.8% vs QoQ 37.3%, YoY 39.2%
EBIDTA came at Rs. 89 Cr (8.8% QoQ, 131.1% YoY) vs expectation of Rs. 79.2 Cr, QoQ Rs. 81.8 Cr, YoY Rs. 38.5 Cr
EBITDA Margin came at 11.2% vs expectation of 10.7%, QoQ 11.1%, YoY 5.5%
Adj. PAT came at Rs. 54.6 Cr vs expectation of Rs. 45.2 Cr, QoQ Rs. 49.5 Cr, YoY Rs. -6.5 Cr
Quarter EPS is Rs. 2.3
Share is trading at P/E of 14.7x FY22E EPS
(Nirmal Bang Retail Research)
*Result is above expectations*
Revenue from Operations came at Rs. 794.1 Cr (7.3% QoQ, 13.8% YoY) vs expectation of Rs. 740.7 Cr, QoQ Rs. 739.8 Cr, YoY Rs. 697.9 Cr
Gross Profit Margins came at 36.8% vs QoQ 37.3%, YoY 39.2%
EBIDTA came at Rs. 89 Cr (8.8% QoQ, 131.1% YoY) vs expectation of Rs. 79.2 Cr, QoQ Rs. 81.8 Cr, YoY Rs. 38.5 Cr
EBITDA Margin came at 11.2% vs expectation of 10.7%, QoQ 11.1%, YoY 5.5%
Adj. PAT came at Rs. 54.6 Cr vs expectation of Rs. 45.2 Cr, QoQ Rs. 49.5 Cr, YoY Rs. -6.5 Cr
Quarter EPS is Rs. 2.3
Share is trading at P/E of 14.7x FY22E EPS
*Torrent Pharmaceuticals Ltd.* | *CMP* Rs. 2731 | *M Cap* Rs. 46215 Cr | *52 W H/L* 3040/2232
(Nirmal Bang Retail Research)
*Result is in-line with expectations*
Revenue from Operations came at Rs. 1937 Cr (-2.9% QoQ, -0.5% YoY) vs expectation of Rs. 1996.8 Cr, QoQ Rs. 1995 Cr, YoY Rs. 1946 Cr
EBIDTA came at Rs. 582 Cr (-4.1% QoQ, 6.2% YoY) vs expectation of Rs. 586.1 Cr, QoQ Rs. 607 Cr, YoY Rs. 548 Cr
EBITDA Margin came at 30% vs expectation of 29.4%, QoQ 30.4%, YoY 28.2%
Adj. PAT came at Rs. 324 Cr vs expectation of Rs. 273.1 Cr, QoQ Rs. 297 Cr, YoY Rs. 314 Cr
Quarter EPS is Rs. 19.1
Share is trading at P/E of 33.3x FY22E EPS
(Nirmal Bang Retail Research)
*Result is in-line with expectations*
Revenue from Operations came at Rs. 1937 Cr (-2.9% QoQ, -0.5% YoY) vs expectation of Rs. 1996.8 Cr, QoQ Rs. 1995 Cr, YoY Rs. 1946 Cr
EBIDTA came at Rs. 582 Cr (-4.1% QoQ, 6.2% YoY) vs expectation of Rs. 586.1 Cr, QoQ Rs. 607 Cr, YoY Rs. 548 Cr
EBITDA Margin came at 30% vs expectation of 29.4%, QoQ 30.4%, YoY 28.2%
Adj. PAT came at Rs. 324 Cr vs expectation of Rs. 273.1 Cr, QoQ Rs. 297 Cr, YoY Rs. 314 Cr
Quarter EPS is Rs. 19.1
Share is trading at P/E of 33.3x FY22E EPS
Super Duper Techno Funda Mid Term Call
Buy Agarind at CMP of 205 - 206 and dips till 195
Sl 187
Targets:- 210 - 213 - 216 - 219 - 222 - 226 - 230+
Above 230 we can see 240 - 255 +
Disclaimer:- I am not SEBI Registered.please consult your financial advisor before investing
BSE - 531921
NSE - 3389
Buy Agarind at CMP of 205 - 206 and dips till 195
Sl 187
Targets:- 210 - 213 - 216 - 219 - 222 - 226 - 230+
Above 230 we can see 240 - 255 +
Disclaimer:- I am not SEBI Registered.please consult your financial advisor before investing
BSE - 531921
NSE - 3389
Short Term Aggressive Call
Buy Astron Paper at CMP of 41.9 - 42.5 and dips of 40
Sl 38
Targets:- 44 - 45 - 46 - 47 - 48 - 49 - 50+
Above 50 we can see 53 - 56 - 60+
Disclaimer:- I am not SEBI Registered. Please consult your financial advisor before investing.
Buy Astron Paper at CMP of 41.9 - 42.5 and dips of 40
Sl 38
Targets:- 44 - 45 - 46 - 47 - 48 - 49 - 50+
Above 50 we can see 53 - 56 - 60+
Disclaimer:- I am not SEBI Registered. Please consult your financial advisor before investing.